International Clinical Psychopharmacology
June 27, 2024
Alberto Sainz-Cort, Marta Martín-Islas, Daniel Jiménez‐garrido et al.
1 citation
OBJECTIVE: While social cognition is shown to be impaired in several mental disorders, the effects of cannabis on social cognition are still not clear. Past studies have used the multifaceted empathy test (MET) to study social cognition. This study aims to test the validity of the MET Spanish version and to evaluate the effects of cannabis use on social cognition. METHODS: In total 116...
Advances in Social Sciences Research Journal
June 24, 2024
Musaed A. Al-Mutairi
This article explores the reinterpretation of the forbidden fruit in the Adam and Eve narrative across Christianity, Judaism, and Islam, proposing that it was cannabis rather than the traditionally accepted apple, fig, grape, or wheat. The story's significance in each religion highlights themes of temptation, disobedience, and moral consequences. The author argues that cannabis, with its...
Schizophrenia Bulletin
June 20, 2024
Mary F. Brunette, Robert M. Roth, Christi L. Trask et al.
5 citations
BACKGROUND AND HYPOTHESIS: Up to 43% of people with schizophrenia have a lifetime cannabis use disorder (CUD). Tetrahydrocannabinol (THC) has been shown to exacerbate psychosis in a dose-dependent manner, but little research has assessed its effects on schizophrenia and co-occurring CUD (SCZ-CUD). In this double-dummy, placebo-controlled trial (total n = 130), we hypothesized that a modest dose...
Cannabis and Cannabinoid Research
June 17, 2024
Madeline K Stanger, Harmony O Soffer, Angela D Bryan et al.
1 citation
Introduction: In Colorado, both cannabis and psilocybin are legal and becoming more commonly used. However, there is almost no research detailing the public health concerns regarding negative outcomes (e.g., dependence) of cannabis and psilocybin co-use and motives that may perpetuate these negative outcomes (e.g., coping, boredom). Methods: Using data from a larger observational study on...
European Archives of Psychiatry and Clinical Neuroscience
June 11, 2024
N. Treves, N. Yakirevich-Amir, W. Abu Ahmad et al.
There is a potential link between cannabis and mental disorders. Cannabis exposure involves in many cases negative mental emotions, which are unpleasant sensations or thoughts. Whereas mild cases of negative mental emotions inflict patient’s quality of life, more severe cases lead to therapy discontinuations, or even hospitalizations and death. This study characterizes cannabis users who...
Progress in Neuro-Psychopharmacology and Biological Psychiatry
June 8, 2024
Jenny L Wiley, Julie A. Marusich, Bruce E. Blough et al.
The cannabis plant contains several cannabinoids, and many terpenoids that give cannabis its distinctive flavoring and aroma. Δ9-Tetrahydrocannabinol (Δ9-THC) is the plant's primary psychoactive constituent. Given the abuse liability of Δ9-THC, assessment of the psychoactive effects of minor cannabinoids and other plant constituents is important, especially for compounds that may be used...
JAMA Health Forum
June 7, 2024
Kevin H. Yang, Nora Satybaldiyeva, Matthew R Allen et al.
16 citations
Despite growing interest in psychedelics, there is a lack of routine population-based surveillance of psychedelic microdosing (taking "subperceptual" doses of psychedelics, approximately one-twentieth to one-fifth of a full dose, over prolonged periods). Analyzing Google search queries can provide insights into public interest and help address this gap. To analyze trends in public interest in...
Addiction
June 6, 2024
Wayne Hall, Keith Humphreys, John Marsden et al.
18 citations
Abstract The turn of the century brought a resurgence of interest in psychedelics as a treatment for addiction and other psychiatric conditions, accompanied by extensive positive media attention and private equity investment. Government regulatory bodies in Australia, Israel, Canada and the United States now permit use of psychedelics for medical purposes. In the United States, citizen action...
Behavioural Pharmacology
June 1, 2024
Lawrence M Carey, Saba Ghodrati, Charles P France
Cannabis is a pharmacologically complex plant consisting of hundreds of potentially active compounds. One class of compounds present in cannabis that has received little attention are terpenes. Traditionally thought to impart aroma and flavor to cannabis, it has become increasingly recognized that terpenes might exert therapeutic effects themselves. Several recent reports have also indicated...
Neuropsychopharmacology
June 1, 2024
Conor H. Murray, Joel Frohlich, Connor J Haggarty et al.
30 citations
Neural complexity correlates with one's level of consciousness. During coma, anesthesia, and sleep, complexity is reduced. During altered states, including after lysergic acid diethylamide (LSD), complexity is increased. In the present analysis, we examined whether low doses of LSD (13 and 26 µg) were sufficient to increase neural complexity in the absence of altered states of consciousness. In...
Journal of Cannabis Research
May 31, 2024
S Zhao, Bruna Brands, Pamela Kaduri et al.
13 citations
Cannabis has been shown to impact driving due to changes produced by delta-9-tetrahydrocannabinol (THC), the psychoactive component of cannabis. Current legal thresholds for blood THC while driving are based predominantly on evidence utilizing smoked cannabis. It is known that levels of THC in blood are lower after eating cannabis as compared to smoking yet the impact of edibles on driving and...
Neuropsychopharmacology
May 28, 2024
Natalie Ertl, Tom P. Freeman, Claire Mokrysz et al.
19 citations
Adolescence is a time of rapid neurodevelopment and the endocannabinoid system is particularly prone to change during this time. Cannabis is a commonly used drug with a particularly high prevalence of use among adolescents. The two predominant phytocannabinoids are Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), which affect the endocannabinoid system. It is unknown whether this...
Schizophrenia Research: Cognition
May 11, 2024
Christopher Dawes, Samuel Joy McGreal, Shivika Marwaha et al.
Aberrant attentional salience has been implicated in the cannabis-psychosis association. Here, history and frequency of cannabis use were examined against changes in overshadowing (OS), a cue competition paradigm that involves salience processing. Additionally, we examined the association between OS and alternative measures of aberrant salience, as well as schizotypy, in a non-clinical adult...
Psychological Medicine
May 9, 2024
J. Selten, Marta Di Forti, Diego Quattrone et al.
BACKGROUND We examined whether cannabis use contributes to the increased risk of psychotic disorder for non-western minorities in Europe. METHODS We used data from the EU-GEI study (collected at sites in Spain, Italy, France, the United Kingdom, and the Netherlands) on 825 first-episode patients and 1026 controls. We estimated the odds ratio (OR) of psychotic disorder for several groups of...
Journal of Cannabis Research
May 3, 2024
Cristian Caprari, Elena Ferri, M. Vandelli et al.
Since its discovery as one of the main components of cannabis and its affinity towards the cannabinoid receptor CB1, serving as a means to exert its psychoactivity, Δ^9-tetrahydrocannabinol (Δ^9-THC) has inspired medicinal chemists throughout history to create more potent derivatives. Initially, the goal was to synthesize chemical probes for investigating the molecular mechanisms behind the...
Journal of Psychopharmacology
May 2024
Kellen M McDonald, Mikki Schantell, Lucy K Horne et al.
Regular cannabis is known to impact higher-order cognitive processes such as attention, but far less is known regarding cognitive flexibility, a component of executive function. Moreover, whether such changes are related to aberrations in the neural oscillatory dynamics serving flexibility remains poorly understood. Quantify the neural oscillatory dynamics serving cognitive flexibility by...
European Neuropsychopharmacology
May 2024
Brooke Manning, Amie C Hayley, Sarah J Catchlove et al.
As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine the neurocognitive effects of commonly prescribed products to ensure associated safety profiles. The present study aims to investigate the acute effects of a standard 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 mg...
CNS Drugs
May 1, 2024
Libat Weizman, Haggai Sharon, Lior Dayan et al.
Disordered autonomic nervous system regulation and supraspinal pain inhibition have been repeatedly described in chronic pain. We aimed to explore the effects of δ-9-tetrahydrocannabinol (THC), an emerging treatment option, on autonomic nervous system and central pain modulation measures in patients with chronic pain. Twelve male patients with chronic radicular neuropathic pain participated in...
American Journal on Addictions
May 1, 2024
Michael Rogan, Julio C Nunes, Catherine Z Xie et al.
2 citations
Childhood trauma (CT) increases addiction vulnerability. We examined CT's impact on delta-9-tetrahydrocannabinol (THC) effects. This is a post-hoc analysis of a randomized, placebo-controlled, crossover trial investigating the effects of oral THC (10, 20 mg) among 25 persons receiving methadone for opioid use disorder (OUD). Greater CT was associated with lower aversive effects from higher THC...
Substance Use & Misuse
April 25, 2024
D. Rubin-Kahana, Kevin Butler, A. Hassan et al.
Abstract Background With increases in cannabis use and potency, there is a need to improve our understanding of the impact of use on cognitive function. Previous research indicates long-term cannabis use may have a negative effect on executive function. Few studies have examined persistence of it in protracted abstinence, and there is limited evidence of predictors of worse cognitive function...